Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-

PET clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation,

with respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related

to our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in Amendment No. 3 to our Registration

Statement on Form S-3, filed with the SEC October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Staff members will be attending Pharma Ed Resources upcoming educational seminar and ... of industry leading speakers, this timely conference will provide Updates & Case Studies ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q ... professional commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion ... by too quickly to process with the naked eye. , Slow motion ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... Technologies Inc. (IVT), a Canadian vaccine development company, announced ... stage company that develops DNA vaccines. This research will ... DepoVax(TM) vaccine delivery system to advance a therapeutic HIV ... deliver FIT Biotech,s GTU(R) MultiHIV DNA vaccine and our ...
... May 26 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" ... ), a leading manufacturer and supplier,of branded ... announced an,agreement to acquire a 37.5% stake ... ("Jiangsu Yanshen") from existing shareholders for a ...
... UPPSALA, Sweden, May 25 Beactica AB, the ... has entered,into an agreement with Cubist Pharmaceuticals, Inc. ... agreement, Beactica will use its Sprint(TM) surface plasmon,resonance ... pathogenic bacteria of interest to Cubist. Financial terms ...
Cached Biology Technology:ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine 2Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 2Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 3
(Date:8/24/2015)... VIEW, Calif. , Aug. 24, 2015  Based on ... Sullivan recognizes DERMALOG with the 2015 African Biometrics Company of ... and has achieved substantial commercial success in Africa ... Nigeria , where it has implemented one of the ... 23 banks as well as the Central Bank of ...
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... statistical model that incorporates the surrounding landscape in unprecedented ... via pollen and seed dispersal in cotton plants more ... graduate student at the University of Arizona,s College of ... their findings in PLoS ONE on Nov. ...
... NY, November 30, 2010Access to quality reproductive healthcare for ... a woman,s human rights, freedom, equity, and right to ... Women,s Reproductive Health in the current issue of Journal ... Ann Liebert, Inc., explores the compelling medical, socioeconomic, and ...
... CA--The Genome 10K Community of Scientists and BGI (formerly the ... to sequence the genomes of 101 vertebrate species within the ... to be sequenced by the Genome 10K Project. ... gather specimens of thousands of animals from zoos, museums, and ...
Cached Biology News:Gene transfer from transgenic crops: A more realistic picture 2Gene transfer from transgenic crops: A more realistic picture 3Ensuring the rights of women worldwide to reproductive health care 2Genome 10K Project announces first 101 species for genome sequencing 2Genome 10K Project announces first 101 species for genome sequencing 3
Request Info...
... Calmodulin Sepharose 4B, ... single-step purification of ... proteins.Purification of calmodulin-regulated ... eukaryotic cells. Category: ...
...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
Biology Products: